Advantages of Off-the-Shelf CAR NK Therapy in B-Cell Malignancies

Video

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

There are several CAR NK products in development at Fate Therapeutics; some products are in clinical trials and some are in preclinical development. The NK cell has 3 modalities: CD19 to target B-cell malignancies, CD16 to be combined with monoclonal antibodies that target B-cell malignancies, and recombinant fusion of interleukin (IL)-15 and IL-15RF, which overcomes the lack of persistence of NK cells, says Valamehr. That trimodality targeted structure, combined with product’s off-the-shelf use, could provide patients with cost-effective therapy in a timely manner.

Research with this platform suggests that an adoptive cell therapy can be converted into a pharmaceutical drug product, says Valamehr. It also suggests that NK cells can be engineered to be more effective. Additionally, the product can house multiple antitumor modalities on 1 cell to overcome the heterogeneity or evolution of cancer growth, concludes Valamehr.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.